Abstract
We report our experience with Chromogenic in Situ Hybridization (CISH) for the evaluation of HER2 amplification on 55 cases of formalin-fixed, paraffin-embedded invasive breast carcinomas of different histology. All the results were corrected for chromosome 17 aneusomy and compared with immunohistochemistry (IHC); a subset of cases was compared to FISH. Thirty-one of 32 cases in which FISH and CISH were performed yielded the same results. CISH and IHC showed a good concordance in the 0/1+ and 3+ category, while a poor agreement with weakly protein overexpression was confirmed. Chromosome 17 analysis was necessary in cases with a low number of HER2 gene copies. CISH is a useful tool to evaluate breast cancer HER2 status that can be easily implemented in a laboratory of surgical pathology.
MeSH terms
-
Breast Neoplasms / chemistry*
-
Breast Neoplasms / diagnosis
-
Breast Neoplasms / genetics
-
Breast Neoplasms / pathology
-
Carcinoma, Ductal / chemistry
-
Carcinoma, Ductal / diagnosis
-
Carcinoma, Ductal / genetics
-
Carcinoma, Ductal / pathology
-
Carcinoma, Lobular / chemistry
-
Carcinoma, Lobular / diagnosis
-
Carcinoma, Lobular / genetics
-
Carcinoma, Lobular / pathology
-
Carcinoma, Papillary / chemistry
-
Carcinoma, Papillary / diagnosis
-
Carcinoma, Papillary / genetics
-
Carcinoma, Papillary / pathology
-
Chromogenic Compounds*
-
Gene Amplification
-
Gene Expression Regulation, Neoplastic
-
Genes, erbB-2 / genetics*
-
Humans
-
Immunohistochemistry / methods*
-
In Situ Hybridization / methods*
-
In Situ Hybridization, Fluorescence / methods*
-
Receptor, ErbB-2 / analysis*
-
Receptor, ErbB-2 / genetics
Substances
-
Chromogenic Compounds
-
Receptor, ErbB-2